Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.54 |
| ▸ | BCL9 | O00512 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FABP3 | P05413 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31112585 | 0.99 | MGLL (0.55) | MGLLBCL9CTNNB1MAPTHTR2A | |
| SCHEMBL16501791 | 0.92 | HTR2A (0.47) | MGLLBCL9CTNNB1MAPTHTR2A | |
| SCHEMBL18599378 | 0.92 | HTR2A (0.47) | MGLLBCL9CTNNB1MAPTHTR2A | |
| SCHEMBL21433779 | 0.92 | MGLL (0.62) | MGLLBCL9CTNNB1MAPTHTR2A | |
| SCHEMBL21777065 | 0.92 | MGLL (0.62) | MGLLBCL9CTNNB1MAPTHTR2A | |
| SCHEMBL21433828 | 0.92 | MGLL (0.62) | MGLLBCL9CTNNB1MAPTHTR2A | |
| SCHEMBL30676193 | 0.92 | MGLL (0.62) | MGLLBCL9CTNNB1MAPTHTR2A | |
| SCHEMBL21433889 | 0.92 | MGLL (0.62) | MGLLBCL9CTNNB1MAPTHTR2A | |
| SCHEMBL9846659 | 0.92 | MGLL (0.62) | MGLLBCL9CTNNB1MAPTHTR2A | |
| SCHEMBL2234364 | 0.92 | MGLL (0.62) | MGLLBCL9CTNNB1MAPTHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024226691-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-12024484-B2 | Lipid formulations for gene editing | VERVE THERAPEUTICS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-1423107-B1 | FATTY ALCOHOL DRUG CONJUGATES | LUITPOLD PHARM INC (US) | 2012-05-09 | — | — | EP | disclosed |
| US-7816398-B2 | Fatty alcohol drug conjugates | LUITPOLD PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816398-B2 | Fatty alcohol drug conjugates | LUITPOLD PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816398-B2 | Fatty alcohol drug conjugates | LUITPOLD PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20080090803-A1 | FATTY ALCOHOL DRUG CONJUGATES | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090803-A1 | FATTY ALCOHOL DRUG CONJUGATES | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090803-A1 | FATTY ALCOHOL DRUG CONJUGATES | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| EP-1423107-A4 | FATTY ALCOHOL DRUG CONJUGATES | LUITPOLD PHARM INC (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1423107-A2 | FATTY ALCOHOL DRUG CONJUGATES | Protarga, Inc. (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20020177609-A1 | Fatty alcohol drug conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-28 | — | — | US | disclosed |
| WO-2002076404-A2 | FATTY ALCOHOL DRUG CONJUGATES | PROTARGA, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177609-A1 | Fatty alcohol drug conjugates | ADH1A, ADH1C, ADH5 | MGLL 107/4885BCL9 401/4885CTNNB1 4754/4885 |
| US-12024484-B2 | Lipid formulations for gene editing | LIPA, LIPC, ABHD16A | MGLL 7/4885BCL9 2689/4885CTNNB1 4876/4885 |
| US-20080090803-A1 | FATTY ALCOHOL DRUG CONJUGATES | ADH1A, ADH1C, ADH5 | MGLL 107/4885BCL9 401/4885CTNNB1 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.